fentanyl has been researched along with Pain, Intractable in 100 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Pain, Intractable: Persistent pain that is refractory to some or all forms of treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our aim was to examine whether, fentanyl as well as morphine, two potent analgesic opioids commonly used to treat cancer pain, would inhibit pain and bone lesion-related responses in a murine model of bone cancer pain." | 7.74 | The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. ( El Mouedden, M; Meert, TF, 2007) |
| " Data from patients with noncancer or cancer pain treated with TD buprenorphine or TD fentanyl for at least 3 months between May 2002 and April 2005 were analyzed." | 7.73 | Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. ( Nuijten, M; Poulsen Nautrup, B; Sittl, R, 2006) |
| "The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation." | 5.14 | Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. ( Kloecker, N; Mueller, M; Nadstawek, J; Schaefer, N; Schenk, M; Schroeck, A; Standop, J; Wirz, S; Wittmann, M, 2009) |
| "A new method of administration of an opioid was recently registered: fentanyl transdermal (brand name: Durogesic), intended particularly for the indication range 'pain in cancer'." | 4.79 | [Transdermal opioid administration: the pain plaster]. ( Sillevis Smitt, PA; Vecht, CJ, 1997) |
| "We report a case of serotonin syndrome caused by interaction between nasal fentanyl, oxycodone and escitalopram." | 3.76 | [Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report]. ( Lefebvre-Kuntz, D; Reich, M, 2010) |
| " Our aim was to examine whether, fentanyl as well as morphine, two potent analgesic opioids commonly used to treat cancer pain, would inhibit pain and bone lesion-related responses in a murine model of bone cancer pain." | 3.74 | The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain. ( El Mouedden, M; Meert, TF, 2007) |
| " Data from patients with noncancer or cancer pain treated with TD buprenorphine or TD fentanyl for at least 3 months between May 2002 and April 2005 were analyzed." | 3.73 | Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. ( Nuijten, M; Poulsen Nautrup, B; Sittl, R, 2006) |
| " The Cmax and AUC0-72 tended to increase with dosage from 2." | 2.79 | Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain. ( Fujii, M; Fujiwara, K; Kobayashi, K; Saito, S; Saito, T; Shimada, K, 2014) |
| "In patients with moderate to severe cancer pain receiving treatment with opioid analgesics, the treatment was switched from the existing opioid analgesic to the 1-day fentanyl patch (the "1-day formulation"), and the efficacy and safety of the 1-day formulation were evaluated." | 2.76 | [Clinical study of one-day fentanyl patch in patients with cancer pain--evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy]. ( Hanaoka, K; Sakata, H; Tomioka, T; Yoshimura, T, 2011) |
| "Dose titration of the 1-day formulation was accomplished in a short period in patients with cancer pain who had been previously untreated with opioid analgesics; the efficacy of the formulation for pain control after repeated dosing was comparable to that of the 3-day formulation, and its tolerability was good." | 2.76 | [Double-blind parallel-group dose-titration study comparing a fentanyl-containing patch formulated for 1-day application for the treatment of cancer pain with Durotep MT Patch]. ( Hanaoka, K; Sakata, H; Tomioka, T; Yoshimura, T, 2011) |
| "Oral morphine was used as breakthrough pain medication during opioid titration." | 2.73 | Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. ( Aielli, F; Casuccio, A; Ferrera, P; Ficorella, C; Fulfaro, F; Gebbia, V; Mangione, S; Mercadante, S; Porzio, G; Riina, S; Verna, L; Villari, P, 2008) |
| "Patients with cancer often are rotated from other opioids to methadone to improve the balance between analgesia and side effects." | 2.71 | Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. ( Benítez-Rosario, MA; Feria, M; Martín-Ortega, JJ; Martínez-Castillo, LP; Salinas-Martín, A, 2004) |
| "Sixty-six patients with cancer-related pain entered an open multicentre study to examine the safety and efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain." | 2.71 | Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. ( Busch, MA; Hanks, GW; Higgs, CM; Nugent, M, 2004) |
| " Safety was assessed by recording the advent of adverse events and efficacy by the evaluating the intensity of breakthrough pain." | 2.71 | [Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study]. ( Camps Herrero, C; Carulla Torrent, J; Cassinello Espinosa, J; Dorta Delgado, J; Jara Sánchez, C; Moreno Nogueira, JA; Valentín Maganto, V, 2005) |
| " Transdermal fentanyl dosage was titrated upwards as required." | 2.70 | Opioids in non-cancer pain: a life-time sentence? ( Dellemijn, PL, 2001) |
| " (2) To estimate the pediatric pharmacokinetic parameters of TTS-fentanyl." | 2.69 | Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates. ( Collins, JJ; Dunkel, IJ; Gupta, SK; Inturrisi, CE; Lapin, J; Palmer, LN; Portenoy, RK; Weinstein, SM, 1999) |
| "Initial dose finding in patients with cancer pain who are started on TTS fentanyl (Duragesic, TTS-F) is often unsatisfactory with currently recommended doses and intervals." | 2.68 | Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. ( de Stoutz, N; Korte, W; Morant, R, 1996) |
| "Forty of 47 cancer patients completed the study with 20 patients in each group." | 2.68 | Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain. ( Chang, CL; Chiu, GL; Tsao, CJ; Wong, JO, 1997) |
| "Use of prescription opioids for cancer pain according to the World Health Organization analgesic ladder has been accepted in Japan." | 2.52 | [Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients]. ( Kawakami, J; Naito, T, 2015) |
| "Fentanyl sublingual was generally well tolerated in the two trials and most adverse events were mild to moderate in intensity." | 2.46 | Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. ( Chwieduk, CM; McKeage, K, 2010) |
| " Long-acting oral opioids supply satisfactory analgesia at more convenient dosing intervals." | 2.43 | Advances in opioid therapy and formulations. ( Walsh, D, 2005) |
| "Breakthrough pain in patients with cancer is a common problem with characteristics that make it difficult to treat." | 2.43 | Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review. ( Gordon, DB, 2006) |
| "Patients with moderate to severe malignancy-related pain frequently require the use of opioid pharmacotherapy." | 2.43 | Transdermal opioids for cancer pain. ( Skaer, TL, 2006) |
| " Latency is a much less important problem for chronic administration in cancer pain." | 2.39 | [Transcutaneous fentanyl]. ( Estève, M, 1994) |
| "The use of TDF for the treatment of cancer pain is not associated with impairment in cognitive performance." | 1.40 | [The cognitive effects of using transdermal fentanyl in cancer pain]. ( Ali, A; Bilen, A; Turgut, N; Türkmen, A; Unlü, N, 2014) |
| "Demographic data, cancer type, duration of pain, side effects, visual analog scale (VAS) score, treatment assessment scale (TAS) score, TDF dosage, and the number of patients in whom therapy has been terminated were recorded." | 1.38 | [Comparison of transdermal fentanyl for the management of cancer pain in adults and elders]. ( Ali, A; Alkan, I; Altan, A; Bilen, A, 2012) |
| " 33 patients in terminal stage of carcinoma, who had been treated by transdermal fentanyl due to their excruciating pain (7-10 mark on numerical scale) with initial dosage of 25 microg as a strong opiate analgesic, were monitored within the time period of 10 days." | 1.36 | Treatment of severe cancer pain by transdermal fentanyl. ( Husić, S; Ljuca, D, 2010) |
| "The fentanyl patch was equally divided by drawing a line on the side on which the product name and dose were written." | 1.35 | [Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain]. ( Hoka, S; Kokubun, H; Matoba, M; Okazaki, M; Yago, K, 2008) |
| "Fentanyl has been used for cancer pain in transdermal formulation." | 1.35 | Validated LC coupled to ESI-MS/MS analysis for fentanyl in human plasma and UV analysis in applied reservoir transdermal patches using a simple and rapid procedure. ( Kagawa, Y; Kawakami, J; Mino, Y; Naito, T; Takashina, Y, 2009) |
| " Six patients receiving TTS BU were switched to TTS FE and then rotated back to TTS BU with the same dosing considerations." | 1.34 | Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. ( Aielli, F; Casuccio, A; Ficorella, C; Fulfaro, F; Intravaia, G; Mangione, S; Mercadante, S; Porzio, G; Riina, S; Verna, L, 2007) |
| "Basing on the components and the endurable dosage of each component for children, we formulated the appropriate dosage and usage of a few analgesics (including sustained release tablets of morphine, oxycodone and transdermal fantanyl) available in China, most of which were used in adults." | 1.34 | [Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy]. ( Lin, H; Ling, JY; Luo, WB; Sun, XF; Xia, Y; Zhen, ZJ; Zheng, L, 2007) |
| "The fentanyl patch is a useful agent to control severe cancer pain because of excellent analgesic effect, less adverse effects and more convenience as well as itsundesirable characteristics when transition of patients to home-care is considered or oral administration should be avoided." | 1.34 | [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations]. ( Akiyama, Y; Iseki, M; Ishii, K; Izawa, R; Miyazaki, T; Tani, Y; Yamaguchi, S, 2007) |
| "Eighteen patients with cancer receiving transdermal fentanyl with uncontrolled pain and/or moderate to severe opioid adverse effects, were switched to oral methadone using an initial fixed ratio of 1:20." | 1.34 | Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. ( Casuccio, A; Ferrera, P; Gambaro, V; Mercadante, S; Villari, P, 2007) |
| "The vast majority of patients with cancer pain are prescribed opioids in oral formulation." | 1.33 | [Parenteral opioids in end-of-life care in cancer patients]. ( Hattori, S; Kimura, N; Noguchi, T; Takatani, J, 2005) |
| "The mechanisms responsible for neuropathic pain are not fully understood." | 1.33 | [Transdermal fentanyl for neuropathic pain: a case report]. ( Kara, I; Otelcioğlu, S; Reisli, R; Tuncer, S, 2006) |
| "The efficacy and QOL in a cancer pain patient who converted to transdermal fentanyl from low-dose morphine (n=5) or high-dose morphine (n=5) were retrospectively compared." | 1.33 | [Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life]. ( Akashi, T; Aoki, T; Tachibana, M; Yamazaki, M, 2006) |
| " During the long-term treatment, the transdermal fentanyl dosage had to be increased." | 1.32 | [Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl]. ( Fujimoto, M; Kuroda, T; Mizutani, Y; Sakuyama, T; Yanaga, K, 2004) |
| " No systemic adverse events were noted; two patients reported nasal itching or discomfort on first use that disappeared with repeated use." | 1.31 | An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study. ( Zeppetella, G, 2000) |
| "1 mg/hour of methadone may be safe and effective." | 1.31 | Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. ( Fischberg, DJ; Khojainova, N; Kornick, C; Manfredi, P; Payne, R; Primavera, LH; Santiago-Palma, J, 2001) |
| "Both morphine and fentanyl were used." | 1.30 | Nurse-controlled analgesia using a patient-controlled analgesia device: an alternative strategy in the management of severe cancer pain in children. ( Cooper, MG; Kanagasundaram, SA; Lane, LJ, 1997) |
| "Ten patients with advanced cancer and breakthrough pain between the ages of 39 and 78 received oral transmucosal fentanyl citrate (10-15 micrograms/kg) 4 or 5 times each over 2 days (42 total administrations) in an open study." | 1.28 | An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. ( De Boer, JA; Fine, PG; Marcus, M; Van der Oord, B, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (6.00) | 18.7374 |
| 1990's | 20 (20.00) | 18.2507 |
| 2000's | 52 (52.00) | 29.6817 |
| 2010's | 22 (22.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilen, A | 4 |
| Ali, A | 4 |
| Baturay, F | 2 |
| Ozcan, B | 1 |
| Altan, A | 3 |
| Meissner, W | 1 |
| Sabatowski, R | 1 |
| Beutlhauser, T | 1 |
| Oeltjenbruns, J | 1 |
| Schäfer, M | 1 |
| Ibuki, T | 1 |
| Saito, T | 1 |
| Fujii, M | 1 |
| Saito, S | 1 |
| Shimada, K | 1 |
| Fujiwara, K | 1 |
| Kobayashi, K | 1 |
| Corli, O | 1 |
| Roberto, A | 1 |
| Ertaş, IE | 1 |
| Sehirali, S | 1 |
| Ozsezgin Ocek, S | 1 |
| Sancı, M | 1 |
| Arbak, G | 1 |
| Yıldırım, Y | 1 |
| Yoshitake, A | 1 |
| Yamamoto, T | 1 |
| Susaki, S | 1 |
| Abe, E | 1 |
| Unlü, N | 1 |
| Turgut, N | 1 |
| Türkmen, A | 1 |
| Naito, T | 2 |
| Kawakami, J | 2 |
| Hayek, SM | 1 |
| Sweet, JA | 1 |
| Miller, JP | 1 |
| Sayegh, RR | 1 |
| Hair, PI | 1 |
| Keating, GM | 1 |
| McKeage, K | 2 |
| Wirz, S | 1 |
| Wittmann, M | 1 |
| Schenk, M | 1 |
| Schroeck, A | 1 |
| Schaefer, N | 1 |
| Mueller, M | 1 |
| Standop, J | 1 |
| Kloecker, N | 1 |
| Nadstawek, J | 1 |
| Goodman, SR | 1 |
| Smiley, RM | 1 |
| Negron, MA | 1 |
| Freedman, PA | 1 |
| Landau, R | 1 |
| Einarson, A | 1 |
| Bozzo, P | 1 |
| Taguchi, N | 1 |
| Matsui, T | 1 |
| Kojima, T | 1 |
| Kojima, H | 1 |
| Iwamoto, N | 1 |
| Kure, S | 1 |
| Uemura, T | 1 |
| Fujimitsu, Y | 1 |
| Sakamoto, J | 1 |
| Matsuyama, K | 1 |
| Satomi, E | 1 |
| Ueno, H | 1 |
| Inoue, A | 1 |
| Oike, M | 1 |
| Todaka, K | 1 |
| Yoshida, T | 1 |
| Sekiyama, R | 1 |
| Hirotsune, H | 1 |
| Sueta, K | 1 |
| Miyamoto, A | 1 |
| Nakamori, S | 1 |
| Tsujinaka, T | 1 |
| Komori, K | 1 |
| Takashina, Y | 1 |
| Mino, Y | 1 |
| Kagawa, Y | 1 |
| Jacobsen, R | 1 |
| Møldrup, C | 1 |
| Christrup, L | 1 |
| Ljuca, D | 1 |
| Husić, S | 1 |
| Reich, M | 1 |
| Lefebvre-Kuntz, D | 1 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Yun, SC | 1 |
| Roh, SW | 1 |
| Rhim, SC | 1 |
| Kim, CJ | 1 |
| Jeon, SR | 1 |
| Chwieduk, CM | 1 |
| Hanaoka, K | 2 |
| Yoshimura, T | 2 |
| Tomioka, T | 2 |
| Sakata, H | 2 |
| Alkan, I | 1 |
| Hisada, T | 1 |
| Katoh, M | 1 |
| Hitoshi, K | 1 |
| Kondo, Y | 2 |
| Fujioka, M | 1 |
| Toyama, Y | 1 |
| Ieda, H | 1 |
| Gocho, S | 1 |
| Nadai, M | 1 |
| Enting, RH | 1 |
| Oldenmenger, WH | 1 |
| van der Rijt, CC | 1 |
| Wilms, EB | 1 |
| Elfrink, EJ | 1 |
| Elswijk, I | 1 |
| Sillevis Smitt, PA | 2 |
| Chen, DY | 1 |
| Lu, MS | 1 |
| Tan, MY | 1 |
| Carter, AC | 1 |
| Nicholas, JJ | 1 |
| Mystakidou, K | 1 |
| Tsilika, E | 1 |
| Parpa, E | 1 |
| Kouloulias, V | 1 |
| Kouvaris, I | 1 |
| Georgaki, S | 1 |
| Vlahos, L | 1 |
| Tennant, F | 1 |
| Hermann, L | 1 |
| Yu, SY | 2 |
| Sun, Y | 2 |
| Zhang, HC | 2 |
| Wu, YL | 2 |
| Qin, SK | 2 |
| Xie, GR | 2 |
| Liu, SJ | 2 |
| Sui, G | 1 |
| Taha, J | 1 |
| Favre, J | 1 |
| Janszen, M | 1 |
| Galarza, M | 1 |
| Taha, A | 1 |
| Yoshizawa, A | 1 |
| Gyouda, Y | 1 |
| Ishiguro, T | 1 |
| Yoshizawa, T | 1 |
| Yoshida, S | 1 |
| Benítez-Rosario, MA | 1 |
| Feria, M | 1 |
| Salinas-Martín, A | 1 |
| Martínez-Castillo, LP | 1 |
| Martín-Ortega, JJ | 1 |
| Walsh, D | 1 |
| Hanks, GW | 2 |
| Nugent, M | 1 |
| Higgs, CM | 1 |
| Busch, MA | 2 |
| Fujimoto, M | 1 |
| Sakuyama, T | 1 |
| Mizutani, Y | 1 |
| Kuroda, T | 1 |
| Yanaga, K | 1 |
| Hattori, S | 1 |
| Kimura, N | 1 |
| Takatani, J | 1 |
| Noguchi, T | 1 |
| Reid, C | 1 |
| Bozkurt, P | 1 |
| Bakan, M | 1 |
| Kilinç, LT | 1 |
| Oltmanns, KM | 1 |
| Fehm, HL | 1 |
| Peters, A | 1 |
| Jung, BF | 1 |
| Reidenberg, MM | 1 |
| Valentín Maganto, V | 1 |
| Camps Herrero, C | 1 |
| Carulla Torrent, J | 1 |
| Cassinello Espinosa, J | 1 |
| Dorta Delgado, J | 1 |
| Jara Sánchez, C | 1 |
| Moreno Nogueira, JA | 1 |
| Sui, GJ | 1 |
| Shinjo, T | 1 |
| Okada, M | 1 |
| Finkel, JC | 1 |
| Finley, A | 1 |
| Greco, C | 1 |
| Weisman, SJ | 1 |
| Zeltzer, L | 1 |
| Yamazaki, M | 1 |
| Aoki, T | 1 |
| Tachibana, M | 1 |
| Akashi, T | 1 |
| Gordon, DB | 1 |
| Kamiya, N | 1 |
| Yasogawa, Y | 1 |
| Nishi, Y | 1 |
| Takahashi, Y | 1 |
| Hirai, T | 1 |
| Sakurai, M | 1 |
| Masumizu, K | 1 |
| Onosato, W | 1 |
| Koyama, T | 1 |
| Skaer, TL | 1 |
| Sittl, R | 1 |
| Nuijten, M | 1 |
| Poulsen Nautrup, B | 1 |
| Akiyama, Y | 1 |
| Iseki, M | 1 |
| Izawa, R | 1 |
| Ishii, K | 1 |
| Miyazaki, T | 1 |
| Yamaguchi, S | 1 |
| Tani, Y | 1 |
| Tuncer, S | 1 |
| Reisli, R | 1 |
| Kara, I | 1 |
| Otelcioğlu, S | 1 |
| Mercadante, S | 3 |
| Villari, P | 2 |
| Ferrera, P | 2 |
| Casuccio, A | 3 |
| Gambaro, V | 1 |
| El Mouedden, M | 1 |
| Meert, TF | 1 |
| Hashizume, T | 1 |
| Tomiyasu, S | 1 |
| Yomiya, K | 1 |
| Yoshimoto, T | 1 |
| Harada, A | 1 |
| Matoba, M | 2 |
| Porzio, G | 2 |
| Fulfaro, F | 2 |
| Aielli, F | 2 |
| Verna, L | 2 |
| Ficorella, C | 2 |
| Riina, S | 2 |
| Intravaia, G | 1 |
| Mangione, S | 2 |
| Zhen, ZJ | 1 |
| Sun, XF | 1 |
| Xia, Y | 1 |
| Ling, JY | 1 |
| Zheng, L | 1 |
| Luo, WB | 1 |
| Lin, H | 1 |
| Kokubun, H | 1 |
| Okazaki, M | 1 |
| Hoka, S | 1 |
| Yago, K | 1 |
| Gebbia, V | 1 |
| Wright, RM | 1 |
| Goroszeniuk, T | 1 |
| Gourlay, GK | 1 |
| Cousins, MJ | 1 |
| Singler, RC | 1 |
| Zenz, M | 1 |
| Donner, B | 1 |
| Strumpf, M | 1 |
| Singer, M | 1 |
| Noonan, KR | 1 |
| Korte, W | 2 |
| Estève, M | 1 |
| de Stoutz, N | 1 |
| Morant, R | 1 |
| Leelanuntakit, S | 1 |
| Fainsinger, RL | 1 |
| Bruera, E | 2 |
| Grond, S | 1 |
| Zech, D | 1 |
| Lehmann, KA | 1 |
| Radbruch, L | 1 |
| Breitenbach, H | 1 |
| Hertel, D | 1 |
| Wong, JO | 1 |
| Chiu, GL | 1 |
| Tsao, CJ | 1 |
| Chang, CL | 1 |
| Vecht, CJ | 1 |
| Kanagasundaram, SA | 1 |
| Cooper, MG | 1 |
| Lane, LJ | 1 |
| Gordon, RL | 1 |
| Watanabe, S | 1 |
| Pereira, J | 1 |
| Hanson, J | 1 |
| Collins, JJ | 1 |
| Dunkel, IJ | 1 |
| Gupta, SK | 1 |
| Inturrisi, CE | 1 |
| Lapin, J | 1 |
| Palmer, LN | 1 |
| Weinstein, SM | 1 |
| Portenoy, RK | 3 |
| Payne, R | 2 |
| Coluzzi, P | 1 |
| Raschko, JW | 1 |
| Lyss, A | 1 |
| Frigerio, V | 1 |
| Ingham, J | 1 |
| Loseth, DB | 1 |
| Nordbrock, E | 1 |
| Rhiner, M | 1 |
| Pasero, C | 1 |
| McCaffery, M | 1 |
| Chiang, JS | 1 |
| Zeppetella, G | 1 |
| Farrar, JT | 1 |
| Berlin, JA | 1 |
| Kinman, JL | 1 |
| Strom, BL | 1 |
| Bleeker, CP | 1 |
| Bremer, RC | 1 |
| Dongelmans, DA | 1 |
| van Dongen, RT | 1 |
| Crul, BJ | 1 |
| Dellemijn, PL | 1 |
| Santiago-Palma, J | 1 |
| Khojainova, N | 1 |
| Kornick, C | 1 |
| Fischberg, DJ | 1 |
| Primavera, LH | 1 |
| Manfredi, P | 1 |
| Rodos, JJ | 1 |
| Burton, A | 1 |
| Kalso, E | 1 |
| Hassenbusch, SJ | 1 |
| Stanton-Hicks, MD | 1 |
| Soukup, J | 1 |
| Covington, EC | 1 |
| Boland, MB | 1 |
| Fine, PG | 2 |
| Marcus, M | 1 |
| De Boer, JA | 1 |
| Van der Oord, B | 1 |
| Ashburn, MA | 1 |
| Stanley, TH | 1 |
| Ehring, E | 1 |
| Boekstegers, A | 1 |
| Tasker, RR | 1 |
| Organ, LW | 1 |
| Smith, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Randomized, Controlled, Pilot Study Comparing Three Different Anesthesic Techniques for Pregnant Women in Labour: Dural Puncture Epidural, Epidural and Combined Spinal Epidural. Evaluation of the Pain Control and the Hypotension Incidence [NCT05196256] | Phase 3 | 90 participants (Anticipated) | Interventional | 2022-06-30 | Not yet recruiting | ||
| A Randomized Double Blind Clinical Trial Comparing Programed Intermittent Epidural Boluses (PIEB) Versus Patient Controlled Epidural Analgesia (PCEA) With Epidural or Combined Spinal-epidural (CSE) Technique[NCT02768272] | Phase 4 | 240 participants (Actual) | Interventional | 2016-03-01 | Completed | ||
| Evaluation in Efficacy and Safety of Fentanyl-TTS (Durogesic® D-Trans) for Treatment of Chronic Pain[NCT01902524] | Phase 4 | 65 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Study to Assess the Safety, Dose Conversion and Titration of DURAGESIC® (Fentanyl Transdermal System) in Pediatric Subjects With Chronic Pain Requiring Opioid Therapy[NCT00271466] | Phase 3 | 199 participants (Actual) | Interventional | 2000-02-29 | Completed | ||
| Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia[NCT02024568] | Phase 2 | 38 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| Patients' Conscious Experience and Psychological Consequences of Awake Surgery for Intracerebral Lesions[NCT02622529] | 20 participants (Actual) | Observational | 2015-11-30 | Completed | |||
| Evaluation of Pain Before and After Removal of Non-obstructive Kidney Stones[NCT03657667] | 43 participants (Actual) | Interventional | 2018-08-28 | Completed | |||
| Randomized Double-blind Controlled Study to Assess the Efficacy of Intravenous Acetaminophen Associated With Strong Opioids in the Management of Acute Pain in Adult Cancer Patients[NCT04779567] | Phase 4 | 112 participants (Actual) | Interventional | 2019-06-10 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for fentanyl and Pain, Intractable
| Article | Year |
|---|---|
[Breakthrough pain and short-acting opioids].
Topics: Administration, Intranasal; Administration, Mucosal; Analgesics, Opioid; Breakthrough Pain; Delayed- | 2013 |
Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article.
Topics: Administration, Mucosal; Analgesics, Opioid; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplasms; | 2014 |
[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].
Topics: Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2D6; Cytochro | 2015 |
Transdermal matrix fentanyl membrane patch (matrifen): in severe cancer-related chronic pain.
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Disease; Fentanyl; Humans; Neoplasms; Pain, I | 2008 |
Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer.
Topics: Administration, Sublingual; Adult; Analgesics, Opioid; Clinical Trials as Topic; Fentanyl; Humans; N | 2010 |
Advances in opioid therapy and formulations.
Topics: Administration, Cutaneous; Analgesia, Patient-Controlled; Analgesics, Opioid; Chemistry, Pharmaceuti | 2005 |
Contribution to variability in response to opioids.
Topics: Analgesics, Opioid; Biological Availability; Dose-Response Relationship, Drug; Drug Administration S | 2005 |
Interpretation of opioid levels: comparison of levels during chronic pain therapy to levels from forensic autopsies.
Topics: Analgesics, Opioid; Autopsy; Fentanyl; Humans; Methadone; Morphine; Oxycodone; Pain, Intractable | 2005 |
Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
Topics: Administration, Buccal; Administration, Oral; Administration, Sublingual; Analgesics, Opioid; Dose-R | 2006 |
Transdermal opioids for cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Algorithms; Analgesics, Opioid; Buprenorphine; Dose | 2006 |
[Transcutaneous fentanyl].
Topics: Administration, Cutaneous; Chronic Disease; Fentanyl; Humans; Pain, Intractable; Pain, Postoperative | 1994 |
How should we use transdermal fentanyl (TF) for pain management in palliative care patients?
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Canada; Child; Female; Fentanyl; Humans; Male; | 1996 |
[Transdermal opioid administration: the pain plaster].
Topics: Administration, Cutaneous; Analgesics, Opioid; Fentanyl; Humans; Morphine; Pain; Pain, Intractable | 1997 |
New developments in cancer pain therapy.
Topics: Adrenal Medulla; Adrenergic alpha-Agonists; Analgesics, Opioid; Cell Transplantation; Cyclooxygenase | 2000 |
[New opioid preparations in the treatment of pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Clinical Competence; Fentanyl; Humans; Hydromorphone; | 1999 |
25 trials available for fentanyl and Pain, Intractable
| Article | Year |
|---|---|
[Concomitant use of strong and weak opioids in the management of chronic cancer pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Dose-Response Relationship, Drug; Drug Administration | 2013 |
Pharmacokinetics of a new fentanyl tape with a novel delivery system of transdermal matrix patches in patients with cancer pain.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Area Under Curve; Drug Deliv | 2014 |
The effectiveness of subcutaneously implanted epidural ports for relief of severe pain in patients with advanced-stage gynecological cancer: a prospective study.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Epidural Space; Female; Fentanyl; Genital Neopl | 2014 |
Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Antiemetics; Buprenor | 2009 |
A randomized trial of breakthrough pain during combined spinal-epidural versus epidural labor analgesia in parous women.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics, Opioid; Anesthetics, Local; Bupivaca | 2009 |
A randomized trial of breakthrough pain during combined spinal-epidural versus epidural labor analgesia in parous women.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics, Opioid; Anesthetics, Local; Bupivaca | 2009 |
A randomized trial of breakthrough pain during combined spinal-epidural versus epidural labor analgesia in parous women.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics, Opioid; Anesthetics, Local; Bupivaca | 2009 |
A randomized trial of breakthrough pain during combined spinal-epidural versus epidural labor analgesia in parous women.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics, Opioid; Anesthetics, Local; Bupivaca | 2009 |
Evaluation of efficacy and safety of fentanyl transdermal patch (Durogesic D-TRANS) in chronic pain.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Female; Fentanyl; Humans; Male; | 2011 |
[Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Narcotics; Ne | 2010 |
[Clinical study of one-day fentanyl patch in patients with cancer pain--evaluation of the efficacy and safety in relation to treatment switch from opioid analgesic therapy].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dosage Forms; Female; Fentanyl; Humans; Male; M | 2011 |
[Double-blind parallel-group dose-titration study comparing a fentanyl-containing patch formulated for 1-day application for the treatment of cancer pain with Durotep MT Patch].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Dosage Forms; Double-Blind Method; Female; Fent | 2011 |
Self-treatment with oral transmucosal fentanyl citrate to prevent emergency room visits for pain crises: patient self-reports of efficacy and utility.
Topics: Administration, Sublingual; Adult; Aged; Analgesics, Opioid; California; Chronic Disease; Emergency | 2002 |
Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Drug Administratio | 2004 |
Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study.
Topics: Administration, Buccal; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans | 2004 |
[Safety and efficacy of oral trans-mucosal fentanyl citrate in the long-term treatment of breakthrough pain in oncology patients: the ECODIR study].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; | 2005 |
Transdermal fentanyl in the management of children with chronic severe pain: results from an international study.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Child; Child, Preschool; Chronic Disease; | 2005 |
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Analgesia; Analgesics, Opi | 2008 |
Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle A | 1996 |
Management of cancer-related pain with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female | 1996 |
Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Gastrointestinal Neoplasms; Head an | 1997 |
Comparison of oral controlled-release morphine with transdermal fentanyl in terminal cancer pain.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; | 1997 |
Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study.
Topics: Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Injections, Subcutaneous; Male; Neoplasms; Pain, | 1998 |
Transdermal fentanyl in children with cancer pain: feasibility, tolerability, and pharmacokinetic correlates.
Topics: Administration, Cutaneous; Adolescent; Analgesics, Opioid; Child; Feasibility Studies; Fentanyl; Hum | 1999 |
Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Topics: Administration, Oral; Adult; Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Double-Blin | 1999 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Defining the clinically important difference in pain outcome measures.
Topics: Analgesics, Opioid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Confidenc | 2000 |
Opioids in non-cancer pain: a life-time sentence?
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Chronic Disease; Diabetic Neuropathies; | 2001 |
Sufentanil citrate and morphine/bupivacaine as alternative agents in chronic epidural infusions for intractable non-cancer pain.
Topics: Analgesia, Epidural; Analgesics; Bupivacaine; Drug Combinations; Drug Evaluation; Fentanyl; Humans; | 1991 |
60 other studies available for fentanyl and Pain, Intractable
| Article | Year |
|---|---|
[Pain therapy. Treating pain patients with opioid preparations].
Topics: Administration, Cutaneous; Analgesics, Opioid; Chronic Pain; Cooperative Behavior; Drug Therapy, Com | 2013 |
[Fentanyl: fast and furious?].
Topics: Analgesics, Opioid; Breakthrough Pain; Fentanyl; Humans; Neoplasms; Pain; Pain, Intractable | 2013 |
[Transdermal fentanyl patch for the treatment of chronic intractable pain].
Topics: Analgesics, Opioid; Chronic Pain; Fentanyl; Humans; Pain, Intractable; Transdermal Patch | 2013 |
[Opioid combination of transdermal fentanyl and oral oxycodone for pain in a patient with giant-cell tumor of the sacrum].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Opioid; Bone Neoplasms; Drug Adm | 2014 |
[The cognitive effects of using transdermal fentanyl in cancer pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Cognition Disorders; Female; Fentanyl; Humans; Male; | 2014 |
Successful Management of Corneal Neuropathic Pain with Intrathecal Targeted Drug Delivery.
Topics: Adult; Analgesics; Bupivacaine; Cervical Vertebrae; Cornea; Female; Fentanyl; Humans; Infusion Pumps | 2016 |
Use of a fentanyl patch throughout pregnancy.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Fetus; Humans; Pain, Intractable; P | 2009 |
Feasibility study of direct fentanyl patch introduction without prior opioid titration.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Feasibility Studies; Female; Fentanyl; Gastroin | 2009 |
[A case of unresectable advanced pancreatic cancer treated by gemcitabine-based chemotherapy following cancer pain alleviation by low-dose matrix-type transdermal fentanyl].
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fentanyl; G | 2009 |
Validated LC coupled to ESI-MS/MS analysis for fentanyl in human plasma and UV analysis in applied reservoir transdermal patches using a simple and rapid procedure.
Topics: Administration, Cutaneous; Calibration; Chromatography, Liquid; Drug Stability; Fentanyl; Humans; Ne | 2009 |
Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Data Collection; Decision Suppo | 2009 |
Fentanyl effervescent buccal tablets: new formulation. For cancer patients with breakthrough pain: a second buccal formulation with minimal evaluation.
Topics: Administration, Buccal; Analgesics, Opioid; Biological Availability; Chemistry, Pharmaceutical; Dosa | 2009 |
Fentanyl sublingual tablets. Breakthrough pain: new formulation, no therapeutic advantage.
Topics: Administration, Sublingual; Analgesics, Opioid; Chemistry, Pharmaceutical; Fentanyl; Humans; Neoplas | 2010 |
Treatment of severe cancer pain by transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Bone Neoplasms; Female; Fentanyl; Hemody | 2010 |
[Serotoninergic antidepressants and opiate analgesics: a sometimes-painful association. A case report].
Topics: Adenocarcinoma; Administration, Intranasal; Administration, Oral; Aged; Analgesics, Opioid; Antidepr | 2010 |
[Comparison of transdermal fentanyl for the management of cancer pain in adults and elders].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2012 |
A simple liquid chromatography-tandem mass spectrometry method for determination of plasma fentanyl concentration in rats and patients with cancer pain.
Topics: Aged; Analgesics, Opioid; Animals; Chromatography, Liquid; Female; Fentanyl; Humans; Male; Middle Ag | 2013 |
A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Topics: Adolescent; Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Codeine; Female; Fentany | 2002 |
[Clinical study on treatment of protracted pain by continuously administering different dose of fentanyl by ocupoint embedding micropump].
Topics: Acupuncture Points; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Infusion Pumps, Impla | 2001 |
The importance of the complete history in the discovery of a potential suicide: a case report.
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Cyclohexanecarboxy | 2003 |
Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Female; Fentanyl; Humans; Male; Middle Ag | 2003 |
[Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2003 |
Correlation between withdrawal symptoms and medication pump residual volume in patients with implantable SynchroMed pumps.
Topics: Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Analgesics, Opioid; Baclofen; Bupivacaine; Clon | 2004 |
[Usefulness of fentanyl patch in home palliative care].
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Fentanyl; Home Care Services; Humans; Mi | 2003 |
[Home palliative care--2 case reports: a long-term cancer pain management with transdermal fentanyl].
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Female; Fentanyl; Gastrointestinal Neoplasms; H | 2004 |
[Parenteral opioids in end-of-life care in cancer patients].
Topics: Analgesia, Patient-Controlled; Analgesics, Opioid; Delayed-Action Preparations; Drug Administration | 2005 |
[Challenges in the treatment of pain in children with cancer and tunneling of epidural catheter for long term infusion].
Topics: Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Local; Bone Neoplasms; Bupivacaine; Catheteriz | 2005 |
Chronic fentanyl application induces adrenocortical insufficiency.
Topics: Administration, Cutaneous; Adrenal Insufficiency; Anti-Inflammatory Agents; Drug Administration Sche | 2005 |
[Transdermal fentanyl for the management of cancer pain: a survey of 4492 patients].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Child; Ch | 2005 |
[The opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain--a case report].
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Delayed-Action Preparations; Drug Therapy, Com | 2005 |
[Direct conversion from low-dose morphine to transdermal fentanyl: efficacy for cancer pain and quality of life].
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesia; Analgesics, Opioid; Female; Fe | 2006 |
[A case of long-term, high-dose transdermal fentanyl application for lung cancer pain].
Topics: Administration, Cutaneous; Analgesics, Opioid; Bone Neoplasms; Female; Fentanyl; Humans; Lung Neopla | 2006 |
Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Buprenorphine; Dose-R | 2006 |
[Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Analgesics, Opioid; Female; Fentanyl; Humans; Ma | 2007 |
[Transdermal fentanyl for neuropathic pain: a case report].
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Neuralgia; Pain, Int | 2006 |
Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Drug Administration Schedule; Female; Fe | 2007 |
The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Body Weight; Bone and Bones; Bone Neoplasms; Femur; F | 2007 |
[Validity of recommended minimum dose of prior morphine to initiate transdermal fentanyl patch in prescribing information - multicenter survey of on prescriptions by palliative care specialists in Japan].
Topics: Administration, Cutaneous; Administration, Oral; Analgesics, Opioid; Drug Prescriptions; Fentanyl; H | 2007 |
Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Analgesics, Opioid; Buprenorphine; Fem | 2007 |
[Feasibility to treat pediatric cancer pain with analgesics for adults and their efficacy].
Topics: Adolescent; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Co | 2007 |
[Evaluation of the 2.5 mg fentanyl patch, applied using the half-side application procedure in patients with cancer pain].
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Human | 2008 |
Epidural fentanyl for pain of multiple fractures.
Topics: Aged; Anesthesia, Epidural; Female; Femoral Fractures; Fentanyl; Humans; Pain, Intractable | 1980 |
Strong analgesics in severe pain.
Topics: Analgesics, Opioid; Chronic Disease; Cocaine; Fentanyl; Half-Life; Heroin; Humans; Injections, Intra | 1984 |
An improved technique for alcohol neurolysis of the celiac plexus.
Topics: Abdominal Neoplasms; Anesthesia, Local; Celiac Plexus; Chronic Disease; Crohn Disease; Denervation; | 1982 |
Withdrawal symptoms during therapy with transdermal fentanyl (fentanyl TTS)?
Topics: Administration, Cutaneous; Adult; Colonic Neoplasms; Female; Fentanyl; Humans; Middle Aged; Morphine | 1994 |
Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain.
Topics: Adult; Female; Fentanyl; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pain, Intract | 1993 |
Titration with TTS fentanyl systems for previously uncontrolled cancer pain.
Topics: Administration, Cutaneous; Fentanyl; Humans; Neoplasms; Pain, Intractable | 1994 |
Oral morphine termed narcotic standard in severe cancer pain.
Topics: Administration, Oral; Analgesics, Opioid; Delayed-Action Preparations; Fentanyl; Humans; Morphine; N | 1996 |
Nurse-controlled analgesia using a patient-controlled analgesia device: an alternative strategy in the management of severe cancer pain in children.
Topics: Adolescent; Analgesia, Patient-Controlled; Analgesics, Opioid; Child; Child, Preschool; Dose-Respons | 1997 |
Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cathet | 1998 |
Managing breakthrough pain with OTFC.
Topics: Administration, Oral; Analgesics, Opioid; Drug Delivery Systems; Fentanyl; Humans; Pain, Intractable | 1999 |
An assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot study.
Topics: Administration, Intranasal; Aged; Aged, 80 and over; Analgesia; Dose-Response Relationship, Drug; Dr | 2000 |
Inefficacy of high-dose transdermal fentanyl in a patient with neuropathic pain, a case report.
Topics: Administration, Cutaneous; Analgesia, Epidural; Analgesics, Opioid; Anesthetics, Local; Breast Neopl | 2001 |
Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl.
Topics: Adult; Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Drug Administration Schedule; Female | 2001 |
More on end-of-life care.
Topics: Absorption; Administration, Oral; Analgesics, Opioid; Fentanyl; Humans; Mouth Mucosa; Pain Measureme | 2002 |
Pain in Spain could be on the wane.
Topics: Administration, Cutaneous; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Neoplasms; Pain Measu | 2002 |
An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain.
Topics: Administration, Oral; Adult; Aged; Blood Pressure; Fentanyl; Humans; Middle Aged; Mouth Mucosa; Neop | 1991 |
Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: a case report.
Topics: Absorption; Administration, Oral; Fentanyl; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Pain | 1989 |
[Morphologic and histologic changes caused by continuous peridural analgesia in a cancer patient].
Topics: Adenocarcinoma; Anesthesia, Epidural; Bupivacaine; Catheters, Indwelling; Colonic Neoplasms; Fentany | 1986 |
Physiological guidelines for the localization of lesions by percutaneous cordotomy.
Topics: Anesthesia, Local; Cordotomy; Electric Stimulation; Female; Fentanyl; Humans; Pain, Intractable; Rec | 1974 |